Institution
Emory University
Education•Atlanta, Georgia, United States•
About: Emory University is a education organization based out in Atlanta, Georgia, United States. It is known for research contribution in the topics: Population & Medicine. The organization has 51959 authors who have published 122469 publications receiving 6010698 citations.
Topics: Population, Medicine, Cancer, Health care, Poison control
Papers published on a yearly basis
Papers
More filters
TL;DR: In this article, the authors trace the history of marketing practices and illustrate how the advent of mass production, the emergence of middlemen, and the separation of the producer from the consumer in the Industrial era led to a transactional focus of marketing.
1,048 citations
Duke University1, Cleveland Clinic2, University of Alberta3, Stavanger University Hospital4, Pierre-and-Marie-Curie University5, Veterans Health Administration6, University of California, San Francisco7, University of Glasgow8, Université de Montréal9, University of Gothenburg10, University of North Carolina at Chapel Hill11, Charité12, University of Oslo13, Rabin Medical Center14, Johnson & Johnson15, Emory University16, Universidade Federal do Rio Grande do Sul17, Pontifical Catholic University of Chile18, Linköping University19, MetroHealth20, University of California, Los Angeles21, Janssen Pharmaceutica22, University of Maryland, Baltimore23, University of Florida24, University of Pennsylvania25, Dalhousie University26, Ford Motor Company27, Monash University28, Vilnius University29, University of Washington30, Mexican Social Security Institute31, University of Brescia32, Seoul National University33, Mayo Clinic34, Wrocław Medical University35, Mahidol University36, University of Otago37, University of Groningen38, Thomas Jefferson University39
TL;DR: In this article, Nesiritide was not associated with an increase or a decrease in the rate of death and rehospitalization and had a small, nonsignificant effect on dyspnea when used in combination with other therapies.
Abstract: A b s t r ac t Background Nesiritide is approved in the United States for early relief of dyspnea in patients with acute heart failure. Previous meta-analyses have raised questions regarding renal toxicity and the mortality associated with this agent. Methods We randomly assigned 7141 patients who were hospitalized with acute heart failure to receive either nesiritide or placebo for 24 to 168 hours in addition to standard care. Coprimary end points were the change in dyspnea at 6 and 24 hours, as measured on a 7-point Likert scale, and the composite end point of rehospitalization for heart failure or death within 30 days. Results Patients randomly assigned to nesiritide, as compared with those assigned to placebo, more frequently reported markedly or moderately improved dyspnea at 6 hours (44.5% vs. 42.1%, P = 0.03) and 24 hours (68.2% vs. 66.1%, P = 0.007), but the prespecified level for significance (P≤0.005 for both assessments or P≤0.0025 for either) was not met. The rate of rehospitalization for heart failure or death from any cause within 30 days was 9.4% in the nesiritide group versus 10.1% in the placebo group (absolute difference, −0.7 percentage points; 95% confidence interval [CI], −2.1 to 0.7; P = 0.31). There were no significant differences in rates of death from any cause at 30 days (3.6% with nesiritide vs. 4.0% with placebo; absolute difference, −0.4 percentage points; 95% CI, −1.3 to 0.5) or rates of worsening renal function, defined by more than a 25% decrease in the estimated glomerular filtration rate (31.4% vs. 29.5%; odds ratio, 1.09; 95% CI, 0.98 to 1.21; P = 0.11). Conclusions Nesiritide was not associated with an increase or a decrease in the rate of death and rehospitalization and had a small, nonsignificant effect on dyspnea when used in combination with other therapies. It was not associated with a worsening of renal function, but it was associated with an increase in rates of hypotension. On the basis of these results, nesiritide cannot be recommended for routine use in the broad population of patients with acute heart failure. (Funded by Scios; ClinicalTrials.gov number, NCT00475852.)
1,046 citations
Institute for Health Metrics and Evaluation1, Peking Union Medical College2, Chinese Center for Disease Control and Prevention3, National Institute of Occupational Health4, Sun Yat-sen University5, Central South University6, Centers for Disease Control and Prevention7, Fudan University8, University of Melbourne9, Emory University10, Shanghai Jiao Tong University11, Nanjing University12, Duke University13, Wuhan University14, Chongqing Medical University15
TL;DR: The most common non-communicable diseases, including ischaemic heart disease, stroke, chronic obstructive pulmonary disease, and cancers (liver, stomach, and lung), contributed much more to YLLs in 2013 compared with 1990, and road injuries have become a top ten cause of death in all provinces in mainland China.
1,044 citations
TL;DR: An overview of female breast cancer statistics in the United States, including data on incidence, mortality, survival, and screening is provided, in view of the increasing trends in breast cancer incidence rates in black women.
Abstract: In this article, the American Cancer Society provides an overview of female breast cancer statistics in the United States, including data on incidence, mortality, survival, and screening. Approximately 231,840 new cases of invasive breast cancer and 40,290 breast cancer deaths are expected to occur among US women in 2015. Breast cancer incidence rates increased among non-Hispanic black (black) and Asian/Pacific Islander women and were stable among non-Hispanic white (white), Hispanic, and American Indian/Alaska Native women from 2008 to 2012. Although white women have historically had higher incidence rates than black women, in 2012, the rates converged. Notably, during 2008 through 2012, incidence rates were significantly higher in black women compared with white women in 7 states, primarily located in the South. From 1989 to 2012, breast cancer death rates decreased by 36%, which translates to 249,000 breast cancer deaths averted in the United States over this period. This decrease in death rates was evident in all racial/ethnic groups except American Indians/Alaska Natives. However, the mortality disparity between black and white women nationwide has continued to widen; and, by 2012, death rates were 42% higher in black women than in white women. During 2003 through 2012, breast cancer death rates declined for white women in all 50 states; but, for black women, declines occurred in 27 of 30 states that had sufficient data to analyze trends. In 3 states (Mississippi, Oklahoma, and Wisconsin), breast cancer death rates in black women were stable during 2003 through 2012. Widening racial disparities in breast cancer mortality are likely to continue, at least in the short term, in view of the increasing trends in breast cancer incidence rates in black women.
1,043 citations
University of Modena and Reggio Emilia1, Emory University2, University of Pennsylvania3, University College London4, National Institutes of Health5, Johns Hopkins University6, The Catholic University of America7, University of Turin8, Seconda Università degli Studi di Napoli9, University of Siena10, University of Palermo11, University of Cagliari12, Georgetown University13
TL;DR: Exome sequencing data broaden the phenotype of IBMPFD to include motor neuron degeneration, suggest that VCP mutations may account for ∼1%-2% of familial ALS, and provide evidence directly implicating defects in the ubiquitination/protein degradation pathway in motor neurons degeneration.
1,040 citations
Authors
Showing all 52622 results
| Name | H-index | Papers | Citations |
|---|---|---|---|
| Younan Xia | 216 | 943 | 175757 |
| Eric J. Topol | 193 | 1373 | 151025 |
| Bernard Rosner | 190 | 1162 | 147661 |
| Paul G. Richardson | 183 | 1533 | 155912 |
| Peter W.F. Wilson | 181 | 680 | 139852 |
| Dennis S. Charney | 179 | 802 | 122408 |
| Joseph Biederman | 179 | 1012 | 117440 |
| Kenneth C. Anderson | 178 | 1138 | 126072 |
| David A. Weitz | 178 | 1038 | 114182 |
| Lei Jiang | 170 | 2244 | 135205 |
| William J. Sandborn | 162 | 1317 | 108564 |
| Stephen J. Elledge | 162 | 406 | 112878 |
| Ali H. Mokdad | 156 | 634 | 160599 |
| Michael Tomasello | 155 | 797 | 93361 |
| Don W. Cleveland | 152 | 444 | 84737 |